Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA34893 dose-ranging study in bipolar depression
2007-002551-17Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LU AA34893 in bipolar disorder (BD) (5 arms), sponsored by Lundbeck. Primary endpoint: Primary efficacy endpoint. Started Oct 2007; status: completed.
02
Drugs
LU AA34893
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2007-002551-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002551-17.